Comparative Pharmacology
Head-to-head clinical analysis: CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER versus TRAVASOL 3 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER vs TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and calories for protein synthesis and energy metabolism in parenteral nutrition.
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids, electrolytes, and calories (as dextrose). Amino acids are used for protein synthesis, and electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion: 1.5 g/kg/day (amino acids) as part of parenteral nutrition; typical infusion rate 0.8-1.5 g/kg/hr.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour, adjusted to meet metabolic needs. Typical adult daily dose: 0.8-1.5 g amino acids/kg/day, equivalent to 23-43 mL/kg/day of TRAVASOL 3.5%.
None Documented
None Documented
Amino acids have variable individual half-lives; the terminal elimination half-life for the amino acid mixture is approximately 1.5–2 hours, reflecting rapid distribution and metabolism; clinically, cessation of infusion leads to rapid decline in plasma amino acid levels.
Not applicable as a fixed half-life; amino acids have rapid plasma clearance (t1/2 of 10-30 minutes for individual amino acids). Clinical context: Continuous infusion maintains steady state.
Renal (primarily as amino acids and metabolites); >90% of infused amino acids are eliminated via renal excretion as nitrogenous waste (urea, ammonia) and oxidized to CO2 and water; <10% excreted unchanged in bile/feces.
Renal: >95% of infused amino acids and electrolytes are excreted unchanged or as metabolites. Biliary/fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution